Faeth Therapeutics, Inc.(FTH)

Biotechnology · Rockville, MD

$28.64+1.54 (+5.68%)

Delayed quote: Oct 6, 2026, 1:05 PM EDT

PS Ratio: N/A

Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.

The P/S ratio is N/A as of 2026-10-06T17:07:01.608Z.

Stored calculation inputs

Calculation as of: 2026-10-06T17:07:01.608Z.

Quote observation: 2026-10-06T17:05:17.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 738,303,515
TTM revenue · period ending 2026-06-30: -4,851,000

FMP input reference: 2e4786eb28a8a31d15cdec8f673983fbe0ec0b626c310469f8e20e074e44c13d

P/E Ratio|Gross Margin|Revenue Growth|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

FTH PS Ratio Metrics

PS RATIO

N/A

FTH Competitors' PS Ratio

FTH

Faeth Therapeutics, Inc.

Current

Market Cap

$738.30M

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CADL

Candel Therapeutics, Inc.

vs FTH

Market Cap

$736.18M

PS Ratio

N/A

TTM Avg

1076.18

3Y Avg

1003.10

5Y Avg

1003.10

ACHV

Achieve Life Sciences, Inc.

vs FTH

Market Cap

$730.28M

PS Ratio

N/A

TTM Avg

2.39

3Y Avg

2.16

5Y Avg

5.43

AVBP

ArriVent BioPharma, Inc.

vs FTH

Market Cap

$727.50M

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DSGN

Design Therapeutics, Inc.

vs FTH

Market Cap

$752.29M

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CTKB

Cytek Biosciences, Inc.

vs FTH

Market Cap

$718.68M

PS Ratio

3.48

TTM Avg

2.95

3Y Avg

3.49

5Y Avg

6.67

COLL

Collegium Pharmaceutical, Inc.

vs FTH

Market Cap

$714.67M

PS Ratio

0.88

TTM Avg

1.85

3Y Avg

2.06

5Y Avg

2.04

MLAB

Mesa Laboratories, Inc.

vs FTH

Market Cap

$763.75M

PS Ratio

3.06

TTM Avg

2.14

3Y Avg

2.44

5Y Avg

3.85

ATTO

Attovia Therapeutics, Inc.

vs FTH

Market Cap

$764.84M

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

OLMA

Olema Pharmaceuticals, Inc.

vs FTH

Market Cap

$706.51M

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	PS RATIO	TTM	3Y	5Y
Faeth Therapeutics, Inc. (FTH)	$738.30M	N/A	N/A	N/A	N/A
Candel Therapeutics, Inc. (CADL)vs ›	$736.18M	N/A	1076.18	1003.10	1003.10
Achieve Life Sciences, Inc. (ACHV)vs ›	$730.28M	N/A	2.39	2.16	5.43
ArriVent BioPharma, Inc. (AVBP)vs ›	$727.50M	N/A	N/A	N/A	N/A
Design Therapeutics, Inc. (DSGN)vs ›	$752.29M	N/A	N/A	N/A	N/A
Cytek Biosciences, Inc. (CTKB)vs ›	$718.68M	3.48	2.95	3.49	6.67
Collegium Pharmaceutical, Inc. (COLL)vs ›	$714.67M	0.88	1.85	2.06	2.04
Mesa Laboratories, Inc. (MLAB)vs ›	$763.75M	3.06	2.14	2.44	3.85
Attovia Therapeutics, Inc. (ATTO)vs ›	$764.84M	N/A	N/A	N/A	N/A
Olema Pharmaceuticals, Inc. (OLMA)vs ›	$706.51M	N/A	N/A	N/A	N/A

How this was calculated

Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.

Revenue calculation and filing references
Fiscal period	Revenue	Source
Q3 FY2025Period ended 2025-09-30	-$4,851,000	Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-14
Q4 FY2025Period ended 2025-12-31	$0	Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-30
Q1 FY2026Period ended 2026-03-31	$0	Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-15
Q2 FY2026Period ended 2026-06-30	$0	Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-04
TTM revenue	-$4,851,000

The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.

These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.

Sales Valuation

P/S Ratio

N/A

Market Cap / Trailing Twelve-Month Revenue

PS Ratio Formula & Definition

PS Ratio = Market Cap / Revenue (TTM)

The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

PS Ratio: N/A

FTH PS Ratio Metrics

FTH Competitors' PS Ratio

Sales Valuation

PS Ratio Formula & Definition

Related Metrics